 Samer Al Hadidi
Concepts (180)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 38 | 2024 | 2954 | 7.450 |
Why?
| | Hematologic Neoplasms | 5 | 2024 | 99 | 3.140 |
Why?
| | Antibodies, Bispecific | 5 | 2024 | 69 | 2.850 |
Why?
| | Hematopoietic Stem Cell Transplantation | 7 | 2024 | 567 | 2.800 |
Why?
| | Hematology | 3 | 2024 | 24 | 2.660 |
Why?
| | Medical Oncology | 6 | 2024 | 95 | 2.560 |
Why?
| | Clinical Trials as Topic | 6 | 2024 | 466 | 2.470 |
Why?
| | Neoplasms | 8 | 2024 | 1249 | 2.470 |
Why?
| | Immunotherapy, Adoptive | 9 | 2024 | 157 | 2.260 |
Why?
| | Hodgkin Disease | 3 | 2021 | 44 | 2.150 |
Why?
| | Drug Approval | 5 | 2024 | 47 | 1.990 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2024 | 613 | 1.980 |
Why?
| | Humans | 70 | 2024 | 50208 | 1.870 |
Why?
| | Neutropenia | 2 | 2023 | 115 | 1.610 |
Why?
| | Waldenstrom Macroglobulinemia | 2 | 2022 | 40 | 1.560 |
Why?
| | Physicians | 3 | 2024 | 230 | 1.530 |
Why?
| | Transplantation, Autologous | 7 | 2024 | 469 | 1.460 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 990 | 1.330 |
Why?
| | T-Lymphocytes | 6 | 2024 | 339 | 1.300 |
Why?
| | Neoplasms, Second Primary | 2 | 2024 | 78 | 1.110 |
Why?
| | Neoplasms, Plasma Cell | 2 | 2024 | 37 | 1.080 |
Why?
| | Cross-Sectional Studies | 8 | 2024 | 1554 | 1.070 |
Why?
| | United States Food and Drug Administration | 6 | 2024 | 91 | 1.030 |
Why?
| | United States | 13 | 2024 | 4874 | 0.970 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2024 | 53 | 0.970 |
Why?
| | Authorship | 1 | 2024 | 12 | 0.940 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2024 | 95 | 0.900 |
Why?
| | Terminology as Topic | 1 | 2023 | 62 | 0.880 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2023 | 225 | 0.880 |
Why?
| | Awards and Prizes | 1 | 2023 | 17 | 0.860 |
Why?
| | Fractures, Spontaneous | 1 | 2022 | 16 | 0.830 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 1161 | 0.830 |
Why?
| | Periodicals as Topic | 1 | 2022 | 58 | 0.800 |
Why?
| | Thalidomide | 1 | 2024 | 377 | 0.800 |
Why?
| | Lymphoma, B-Cell | 1 | 2022 | 63 | 0.790 |
Why?
| | Patient Participation | 1 | 2022 | 66 | 0.770 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 68 | 0.770 |
Why?
| | Bone Diseases | 1 | 2022 | 99 | 0.760 |
Why?
| | Brain Diseases | 1 | 2021 | 82 | 0.750 |
Why?
| | Antibodies, Monoclonal | 3 | 2024 | 460 | 0.750 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 39 | 0.720 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 449 | 0.720 |
Why?
| | Racism | 1 | 2021 | 60 | 0.690 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 183 | 0.680 |
Why?
| | Quality of Life | 2 | 2022 | 839 | 0.650 |
Why?
| | Healthcare Disparities | 1 | 2022 | 268 | 0.650 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2024 | 51 | 0.640 |
Why?
| | Platinum Compounds | 1 | 2018 | 10 | 0.620 |
Why?
| | Mycosis Fungoides | 1 | 2018 | 28 | 0.610 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 22 | 0.600 |
Why?
| | Subclavian Artery | 1 | 2017 | 19 | 0.600 |
Why?
| | Pruritus | 1 | 2018 | 44 | 0.600 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 9 | 0.600 |
Why?
| | Antithrombin III Deficiency | 1 | 2017 | 3 | 0.600 |
Why?
| | Ulcer | 1 | 2017 | 22 | 0.580 |
Why?
| | Lymphoproliferative Disorders | 1 | 2017 | 26 | 0.580 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2017 | 30 | 0.580 |
Why?
| | Tachycardia, Ventricular | 1 | 2017 | 45 | 0.580 |
Why?
| | Combined Modality Therapy | 4 | 2024 | 636 | 0.570 |
Why?
| | Abdominal Pain | 1 | 2017 | 81 | 0.570 |
Why?
| | Colon | 1 | 2017 | 94 | 0.570 |
Why?
| | Thromboembolism | 1 | 2017 | 54 | 0.560 |
Why?
| | Deglutition Disorders | 1 | 2017 | 77 | 0.560 |
Why?
| | Dexamethasone | 3 | 2024 | 430 | 0.540 |
Why?
| | Diagnosis, Differential | 5 | 2018 | 1043 | 0.540 |
Why?
| | Gangrene | 1 | 2016 | 14 | 0.540 |
Why?
| | Immunosuppressive Agents | 1 | 2017 | 222 | 0.530 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 154 | 0.520 |
Why?
| | Penile Diseases | 1 | 2016 | 16 | 0.520 |
Why?
| | Female | 13 | 2024 | 26635 | 0.510 |
Why?
| | Aspirin | 1 | 2016 | 114 | 0.510 |
Why?
| | Leiomyoma | 1 | 2015 | 25 | 0.500 |
Why?
| | Migraine with Aura | 1 | 2014 | 4 | 0.490 |
Why?
| | Hysterectomy | 1 | 2015 | 88 | 0.490 |
Why?
| | Edema | 1 | 2015 | 69 | 0.480 |
Why?
| | Early Diagnosis | 1 | 2014 | 87 | 0.470 |
Why?
| | Carotid Stenosis | 1 | 2014 | 64 | 0.470 |
Why?
| | Ovarian Neoplasms | 1 | 2018 | 447 | 0.460 |
Why?
| | Adult | 9 | 2024 | 13324 | 0.440 |
Why?
| | Melphalan | 3 | 2023 | 174 | 0.430 |
Why?
| | Brain Ischemia | 1 | 2014 | 161 | 0.430 |
Why?
| | Skin Neoplasms | 1 | 2018 | 492 | 0.420 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 169 | 0.400 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 2 | 2023 | 115 | 0.400 |
Why?
| | Myeloid Differentiation Factor 88 | 2 | 2022 | 33 | 0.400 |
Why?
| | Lung Neoplasms | 1 | 2018 | 605 | 0.400 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 1186 | 0.400 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2023 | 550 | 0.370 |
Why?
| | B-Cell Maturation Antigen | 4 | 2024 | 91 | 0.360 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 486 | 0.340 |
Why?
| | Stroke | 1 | 2014 | 493 | 0.340 |
Why?
| | Middle Aged | 6 | 2024 | 12206 | 0.330 |
Why?
| | Prognosis | 3 | 2024 | 1954 | 0.330 |
Why?
| | Survival Analysis | 2 | 2023 | 666 | 0.320 |
Why?
| | Breast Neoplasms | 1 | 2018 | 1179 | 0.320 |
Why?
| | Conflict of Interest | 2 | 2024 | 25 | 0.290 |
Why?
| | Pulmonary Emphysema | 1 | 2017 | 24 | 0.290 |
Why?
| | Risk Factors | 4 | 2023 | 3629 | 0.290 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2020 | 314 | 0.290 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 233 | 0.280 |
Why?
| | Male | 6 | 2024 | 25399 | 0.270 |
Why?
| | Mutation | 2 | 2022 | 1294 | 0.260 |
Why?
| | Plasma Cells | 2 | 2024 | 223 | 0.260 |
Why?
| | Syndrome | 2 | 2021 | 238 | 0.260 |
Why?
| | Career Choice | 2 | 2024 | 111 | 0.250 |
Why?
| | Treatment Outcome | 4 | 2022 | 5155 | 0.250 |
Why?
| | Phthalimides | 1 | 2024 | 4 | 0.240 |
Why?
| | Piperidones | 1 | 2024 | 5 | 0.240 |
Why?
| | Drug Industry | 1 | 2024 | 38 | 0.230 |
Why?
| | Morpholines | 1 | 2024 | 70 | 0.230 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2024 | 198 | 0.220 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 111 | 0.220 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 121 | 0.220 |
Why?
| | Financing, Organized | 1 | 2023 | 13 | 0.220 |
Why?
| | Societies, Medical | 1 | 2024 | 177 | 0.220 |
Why?
| | Neoplasm, Residual | 2 | 2022 | 165 | 0.220 |
Why?
| | Health Facilities | 1 | 2023 | 42 | 0.210 |
Why?
| | Faculty | 1 | 2022 | 72 | 0.210 |
Why?
| | Certification | 1 | 2022 | 49 | 0.210 |
Why?
| | Patients | 1 | 2022 | 49 | 0.210 |
Why?
| | Social Media | 1 | 2024 | 96 | 0.210 |
Why?
| | Geography | 1 | 2022 | 60 | 0.210 |
Why?
| | Paraproteinemias | 1 | 2022 | 72 | 0.200 |
Why?
| | Blood Coagulation | 1 | 2022 | 56 | 0.200 |
Why?
| | Immunoconjugates | 1 | 2022 | 38 | 0.200 |
Why?
| | Animals | 4 | 2024 | 13246 | 0.200 |
Why?
| | Immunotherapy | 1 | 2024 | 240 | 0.200 |
Why?
| | Patient Selection | 1 | 2023 | 253 | 0.200 |
Why?
| | Transplantation Conditioning | 1 | 2022 | 84 | 0.200 |
Why?
| | Phenylalanine | 1 | 2022 | 128 | 0.190 |
Why?
| | Research Design | 1 | 2023 | 342 | 0.190 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 92 | 0.190 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 106 | 0.190 |
Why?
| | Pyrimidines | 1 | 2022 | 193 | 0.180 |
Why?
| | Maintenance Chemotherapy | 1 | 2020 | 49 | 0.180 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 206 | 0.180 |
Why?
| | Health Status Disparities | 1 | 2022 | 194 | 0.170 |
Why?
| | Disease Progression | 2 | 2023 | 831 | 0.170 |
Why?
| | Pain | 1 | 2022 | 381 | 0.170 |
Why?
| | Anticoagulants | 1 | 2022 | 253 | 0.170 |
Why?
| | Minority Groups | 1 | 2020 | 132 | 0.160 |
Why?
| | Aged | 2 | 2024 | 9405 | 0.160 |
Why?
| | Follow-Up Studies | 1 | 2024 | 2190 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 120 | 0.150 |
Why?
| | Prospective Studies | 1 | 2023 | 2379 | 0.150 |
Why?
| | Vomiting | 1 | 2017 | 75 | 0.150 |
Why?
| | Weight Loss | 1 | 2017 | 238 | 0.130 |
Why?
| | Electrocardiography | 1 | 2017 | 262 | 0.130 |
Why?
| | Carotid Artery, Internal | 1 | 2014 | 24 | 0.120 |
Why?
| | Endarterectomy, Carotid | 1 | 2014 | 62 | 0.120 |
Why?
| | Cerebral Angiography | 1 | 2014 | 97 | 0.120 |
Why?
| | Lower Extremity | 1 | 2015 | 88 | 0.120 |
Why?
| | Aged, 80 and over | 1 | 2020 | 3154 | 0.100 |
Why?
| | Bone Marrow | 2 | 2022 | 363 | 0.090 |
Why?
| | Pregnancy | 1 | 2018 | 2604 | 0.090 |
Why?
| | Young Adult | 1 | 2018 | 3981 | 0.080 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 65 | 0.070 |
Why?
| | Equipment and Supplies | 1 | 2024 | 17 | 0.060 |
Why?
| | Marketing | 1 | 2024 | 23 | 0.060 |
Why?
| | Cystatin M | 1 | 2024 | 20 | 0.060 |
Why?
| | Disclosure | 1 | 2024 | 39 | 0.060 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 18 | 0.060 |
Why?
| | X-Ray Microtomography | 1 | 2024 | 77 | 0.060 |
Why?
| | Antibodies | 1 | 2024 | 154 | 0.060 |
Why?
| | Mice | 2 | 2024 | 5759 | 0.050 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2023 | 93 | 0.050 |
Why?
| | Chromosome Deletion | 1 | 2023 | 140 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2023 | 259 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2022 | 454 | 0.050 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 79 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2022 | 116 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 410 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2023 | 297 | 0.050 |
Why?
| | Genomics | 1 | 2023 | 285 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2022 | 182 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2021 | 104 | 0.040 |
Why?
| | Cohort Studies | 1 | 2023 | 1422 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1416 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 662 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2023 | 1037 | 0.040 |
Why?
|
|
Al Hadidi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|